by Rod Raynovich | Jul 19, 2011 | 2023-24 Life Science Portfolios, Macro
With the QQQ you are still Bullish on Biotech We mentioned yesterday that those wanting to be bullish large cap NASDAQ stocks but remain bullish on biotech would be better off with a QQQ position as pure play biotechs are due for a rest. Today the QQQ is up 1.69%...
by Rod Raynovich | Jul 18, 2011 | 2023-24 Life Science Portfolios, BIOgraph
Todays’ Movers : CSII and IMGN Life Science and Drug stocks hit their third day of selling about 4% off July highs but 6% higher than June lows. The bellwether ETF IBB remains 6% above intermediate support of 100.The healthcare sector overall was down 0.88%...
by Rod Raynovich | Jul 16, 2011 | BIOgraph, Life Science ETF's and Mutual Funds
Edited Version Published in Investor Uprising June 2011 :Updated here JY 16, 2011 Biotechnology Has Outperformed the S&P Over Five Years Medical science has always been an important area for investors and recent breakthroughs with new drugs and devices have...
by Rod Raynovich | Jul 14, 2011 | 2023-24 Life Science Portfolios, BIOgraph, Reading List
Life Science Sector Outperforms NASDAQ-100: Movers are ROSGD, VICL Biotechnology stocks sold off about 0.65% overall as industry news and fundamentals were eclipsed by MACRO issues. Concerns loom about European debt, US debt ceiling and potential default. JPMorgan...
by Rod Raynovich | Jul 12, 2011 | 2023-24 Life Science Portfolios, BIOgraph
Life Science Stocks are Stable in a Choppy Market; Macro Is Dominating The NASDAQ market stabilized today (but down 0.54%) after a two day sell-off that brought the qqq down to $57.79 from the $59.50 level last Thursday.The market skittishness was primarily caused by...
by Rod Raynovich | Jul 5, 2011 | 2023-24 Life Science Portfolios
TPG Capital Offers $1.97B for diagnostic Company focused in blood donor screening. TPG Capital is a private equity firm with $48B in assets. Immucor was added to the Rayno Life Science Portfolio in April 2010 at a price of $20.
by Rod Raynovich | Jun 26, 2011 | 2023-24 Life Science Portfolios, BIOgraph
We will be attending the BIO Meeting in Washington DC and will not be posting as usual. Note that there were two news items over the weekend on our portfolio stocks: A positive article on Gilead (GILD) in Barron’s. Gilead Sciences Shares Could Rally –...
by Rod Raynovich | Jun 21, 2011 | 2023-24 Life Science Portfolios, BIOgraph
The market touched the March lows last Friday , down for the year, and buyers swarmed in.Biotechs were strong yesterday buffering tech weakness and today the baton was passed to several sectors with a broad rally especially with NASDAQ up 2.23%. The NASDAQ-100 qqq...
by Rod Raynovich | Jun 20, 2011 | 2023-24 Life Science Portfolios, BIOgraph
NASDAQ stocks rallied today just off March 2011 QQQ bottoms led by large cap biotech stocks.The NASDAQ 100 is up 0.6% led by Biogen Idec(BIIB) up 4.26%, Celgene (CELG) up 3.27%, and Gilead (GILD) up 1.5%.The rally would be stronger were it not for weak tech stocks...
by Rod Raynovich | Jun 17, 2011 | 2023-24 Life Science Portfolios, BIOgraph
Busy Day Today -Overall a Lot of Green Screen The diagnostics and tools sector has seen resilience over the past 30 days as the market corrected 7% or more.Bellwether large cap tools stocks with revenue growth such as ILMN,NEOG, TMO have held up well helped by M&A...